SCINTIX therapy is the only radiotherapy with the potential to overcome the hurdles of targeting and motion management, especially for multiple tumors, the core challenge in existing external beam radiotherapy approaches. Designated by the U.S. Food and Drug Administration (FDA) as a Breakthrough Device in 2021 for its potential in managing motion in lung tumors, SCINTIX therapy was FDA-cleared in 2023 for treating lung and bone tumors that arise from primary or metastatic disease. Patient treatments also began at several clinical sites in 2023. These milestones usher in a new era of autonomous radiotherapy where the biology of the tumor directs where to deliver the radiation dose.
About RefleXion Medical
Ad Statistics
Times Displayed: 124471
Times Visited: 7225 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided external-beam radiotherapy for solid tumors located anywhere in the body.
Back to HCB News
